Optimum Induction Therapy of Low-risk APL

NCT05832320 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Acute Promyelocytic Leukemia
Induction Therapy
Oral

Interventions

DRUG: Etoposide
DRUG: Daunorubicin

Sponsor

Peking University People's Hospital